Literature DB >> 8701022

Bioactive peptides from lizard venoms.

J P Raufman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8701022     DOI： 10.1016/0167-0115(96)00135-8

Source DB:  PubMed          Journal:  Regul Pept        ISSN： 0167-0115


× No keyword cloud information.
  12 in total

Review 1.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

2.  Assessing sequence-based protein-protein interaction predictors for use in therapeutic peptide engineering.

Authors:  François Charih; Kyle K Biggar; James R Green
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

Review 3.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

4.  Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.

Authors:  T Tolessa; M Gutniak; J J Holst; S Efendic; P M Hellström
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

5.  Expressed Protein Ligation without Intein.

Authors:  Yuchen Qiao; Ge Yu; Kaci C Kratch; Xiaoyan Aria Wang; Wesley Wei Wang; Sunshine Z Leeuwon; Shiqing Xu; Jared S Morse; Wenshe Ray Liu
Journal:  J Am Chem Soc       Date:  2020-04-02       Impact factor: 15.419

6.  Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice.

Authors:  Mitsuteru Akahoshi; Chang Ho Song; Adrian M Piliponsky; Martin Metz; Andrew Guzzetta; Magnus Abrink; Susan M Schlenner; Thorsten B Feyerabend; Hans-Reimer Rodewald; Gunnar Pejler; Mindy Tsai; Stephen J Galli
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

7.  Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.

Authors:  Odile E Levy; Carolyn M Jodka; Shijun Steven Ren; Lala Mamedova; Abhinandini Sharma; Manoj Samant; Lawrence J D'Souza; Christopher J Soares; Diane R Yuskin; Li Jenny Jin; David G Parkes; Krystyna Tatarkiewicz; Soumitra S Ghosh
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

8.  Vasorelaxin: a novel arterial smooth muscle-relaxing eicosapeptide from the skin secretion of the Chinese piebald odorous frog (Odorrana schmackeri).

Authors:  Yuxin Wu; Lei Wang; Chen Lin; Yan Lin; Mei Zhou; Liang Chen; Brian Connolly; Yingqi Zhang; Tianbao Chen; Chris Shaw
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

Review 9.  Evolution of exenatide as a diabetes therapeutic.

Authors:  Sunil Bhavsar; Sunder Mudaliar; Alan Cherrington
Journal:  Curr Diabetes Rev       Date:  2013-03-01

10.  Synthesis and in vivo behaviour of an exendin-4-based MRI probe capable of β-cell-dependent contrast enhancement in the pancreas.

Authors:  Thomas J Clough; Nicoleta Baxan; Emma J Coakley; Charlotte Rivas; Lan Zhao; Isabelle Leclerc; Aida Martinez-Sanchez; Guy A Rutter; Nicholas J Long
Journal:  Dalton Trans       Date:  2020-04-15       Impact factor: 4.390
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.